Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a $10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. ‘We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly,’ Hutchmed Chief Executive Officer Weiguo Su says. ‘It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer.’

On Thursday, Hutchmed said it received breakthrough therapy designation in China for the Orpathys and Tagrisso combination to treat patients with a form of non‑small cell lung cancer. Back in 2011, Hutchmed and AstraZeneca PLC struck a pact to jointly develop and commercialise Orpathys.

Current stock price: 250.00 pence

12-month change: down 17%

Copyright 2024 Alliance News Ltd. All Rights Reserved.